Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAEN HUSSEIN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1356332506
CMS profile
333099
Location
TAVARES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$15,190.80

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAEN HUSSEIN

NPI 1356332506 · CMS profile ID 333099

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TAVARES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $15,190.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $22.4309/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788145429 CMS
Rigel Pharmaceuticals, Inc. $19.5909/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854327339 CMS
Daiichi Sankyo Inc. $34.9909/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836322463 CMS
GENZYME CORPORATION $13.8909/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843580883 CMS
JAZZ PHARMACEUTICALS INC. $11.6908/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845555923 CMS
AstraZeneca Pharmaceuticals LP $16.2008/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834349163 CMS
Eisai Inc. $13.8308/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817983471 CMS
PFIZER INC. $19.2608/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832817499 CMS
E.R. Squibb & Sons, L.L.C. $18.5308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783603465 CMS
Genentech USA, Inc. $14.6508/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835943533 CMS
Amgen Inc. $16.4208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825568335 CMS
Eisai Inc. $21.2208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817975615 CMS
Genentech USA, Inc. $15.4708/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835943545 CMS
AstraZeneca Pharmaceuticals LP $16.9008/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834326301 CMS
Seagen Inc. $15.0708/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832177435 CMS
Ipsen Biopharmaceuticals, Inc $14.9308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841906309 CMS
Karyopharm Therapeutics Inc. $12.2408/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845786815 CMS
Pharmacyclics LLC, An AbbVie Company $12.9608/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781011241 CMS
Seagen Inc. $19.7108/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832177433 CMS
TerSera Therapeutics LLC $40.5108/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851045171 CMS
Eisai Inc. $19.3108/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817973863 CMS
Incyte Corporation $16.9008/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835537085 CMS
AstraZeneca Pharmaceuticals LP $12.3907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834338133 CMS
AstraZeneca Pharmaceuticals LP $21.7707/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834340019 CMS
JAZZ PHARMACEUTICALS INC. $14.1807/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845549765 CMS
GlaxoSmithKline, LLC. $13.0607/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802018261 CMS
Eisai Inc. $19.5307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817969421 CMS
Foundation Medicine, Inc. $17.3507/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799850987 CMS
Lilly USA, LLC $17.4207/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818584927 CMS
AstraZeneca Pharmaceuticals LP $15.9007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834317673 CMS
Amgen Inc. $25.1607/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826384295 CMS
Boehringer Ingelheim International GmbH $2,094.0107/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822295127 CMS
Genentech USA, Inc. $15.1107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835943529 CMS
Pharmacyclics LLC, An AbbVie Company $11.3007/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781011239 CMS
GlaxoSmithKline, LLC. $19.2607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802523139 CMS
Janssen Biotech, Inc. $20.3307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788145443 CMS
Blueprint Medicines Corporation $15.8106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848928131 CMS
GENZYME CORPORATION $20.3006/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843580849 CMS
Heron Therapeutics, Inc. $17.3506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781449779 CMS
Janssen Biotech, Inc. $17.1806/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788145445 CMS
Seagen Inc. $20.2506/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832177393 CMS
Janssen Biotech, Inc. $19.8906/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788145439 CMS
Astellas Pharma US Inc $16.7606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821374745 CMS
Amgen Inc. $5.8106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826384291 CMS
Amgen Inc. $14.8606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826384293 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763534976 CMS
PFIZER INC. $19.7506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832635273 CMS
AstraZeneca Pharmaceuticals LP $17.4906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345963 CMS
Gilead Sciences, Inc. $12.5706/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848212819 CMS
Global Blood Therapeutics, Inc. $12.9806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835340015 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,472.79 202
PY2020 $17,756.11 165
PY2021 $15,190.80 174
PY2022 $13,931.99 204
PY2023 $37,505.72 196
PY2024 $27,554.14 184
PY2025 $34,641.19 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,360.00 5
PY2025 Principal investigator $340,884.19 528
PY2024 Recipient $4,800.00 4
PY2024 Principal investigator $377,134.00 130
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $1,844,755.17 186
PY2022 Recipient $5,052.00 3
PY2022 Principal investigator $1,596,086.63 191
PY2021 Recipient $1,949.97 2
PY2021 Principal investigator $1,569,652.65 275
PY2020 Recipient $4,659.12 1
PY2020 Principal investigator $2,574,107.72 208
PY2019 Recipient $1,031.25 1
PY2019 Principal investigator $9,876,266.37 161

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

533 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644979
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644981
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644983
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644985
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644987
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644989
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644991
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644993
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644995
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644997
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644999
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645001
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645003
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645005
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645007
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645009
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645011
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645013
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645015
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645017
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645019
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645021
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645023
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645025
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645027
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645029
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645031
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645033
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645035
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645037
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645039
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645041
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645043
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645045
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645047
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645049
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645051
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645053
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645055
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645057
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645059
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645061
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645063
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645065
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645067
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645069
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645071
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645073
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645075
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645077
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645079
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645081
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645083
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645085
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645087
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645089
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645091
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645093
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645095
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645097
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645099
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645101
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645103
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644849
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644851
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644853
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644855
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644857
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644859
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644861
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644863
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644865
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644867
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644869
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644871
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644873
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644875
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644877
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644879
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644881
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644883
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644885
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644887
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644889
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644891
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644893
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644895
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644897
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644899
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644901
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644903
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644905
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644907
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644909
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644911
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644913
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644915
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644917
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644919
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644921
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644923
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644925
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644927
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644929
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644931
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644933
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644935
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644937
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644939
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644941
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644943
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644945
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644947
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644949
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644951
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644953
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644955
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644957
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644959
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644961
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644963
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644965
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644967
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644969
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644971
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644973
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644975
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220644977
Principal investigator 1 AstraZeneca Pharmaceuticals LP $796.89 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB IIIA non small cell lung carcinoma following complete tumour resection with or without adjuvant chemotherapy No dispute reported 06/30/2026 1185538725
Principal investigator 1 Genentech, Inc. $83.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211652446
Principal investigator 1 Genentech, Inc. $250.00 10/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211652391
Principal investigator 1 Aadi Bioscience, Inc. $75.00 10/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946915
Principal investigator 1 BeOne Medicines Ltd. $300.00 10/21/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190333171
Recipient PFIZER INC. $940.00 10/19/2025 Covered Recipient Physician BINIMETINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804052
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645703
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645705
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645707
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645709
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645711
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645713
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645715
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645717
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645719
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645721
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645723
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645725
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645727
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645729
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645731
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645733
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645735
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645737
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645739
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645741
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645743
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645745
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645747
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645749
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645751
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645753
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645755
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645757
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645759
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645761
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645763
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645765
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645767
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645769
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645771
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645773
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645775
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645777
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645779
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645781
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645783
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645785
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645787
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645789
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645791
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645793
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645795
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645797
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645799
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645801
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645803
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645805
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645807
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645809
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645811
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645813
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645815
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645817
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645819
Principal investigator 1 BeOne Medicines Ltd. $1,950.00 09/16/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190333164
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645583
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645585
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645587
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645589
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645591
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645593
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645595
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645597
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645599
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645601
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645603
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645605
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645607
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645609
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645611
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645613
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645615
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645617
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645619
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645621
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645623
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645625
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645627
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645629
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645631
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645633
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645635
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645637
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645639
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645641
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645643
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645645
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645647
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645649
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645651
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645653
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645655
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645657
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645659
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645661
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645663
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645665
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645667
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645669
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645671
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645673
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645675
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645677
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645679
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645681
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645683
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645685
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645687
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645689
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645691
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645693
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645695
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645697
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645699
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645701
Principal investigator 1 ARRAY BIOPHARMA INC $1,729.00 08/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228833500
Recipient PFIZER INC. $1,820.00 08/22/2025 Covered Recipient Physician DACOMITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804047
Principal investigator 1 Genentech, Inc. $506.70 08/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211651669
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 08/12/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190333159
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645459
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645461
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645463
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645465
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645467
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645469
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645471
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645473
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645475
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645477
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645479
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645481
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645483
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645485
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645487
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645489
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645491
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645493
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645495
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645497
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645499
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645501
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645503
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645505
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645507
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645509
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645511
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645513
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645515
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645517
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645519
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645521
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645523
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645525
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645527
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645529
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645531
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645533
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645535
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645537
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645539
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645541
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645543
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645545
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645547
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645549
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645551
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645553
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645555
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645557
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645559
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645561
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645563
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645565
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645567
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645569
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645571
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645573
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645575
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645577
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645579
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645581
Principal investigator 1 Genentech, Inc. $354.00 07/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211649164
Principal investigator 1 Aadi Bioscience, Inc. $156.25 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946911
Principal investigator 1 Aadi Bioscience, Inc. $375.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946913
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 07/15/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190333168
Principal investigator 1 Genentech, Inc. $9,876.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211649177
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645359
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645361
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645363
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645365
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645367
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645369
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645371
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645373
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645375
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645377
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645379
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645381
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645383
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645385
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645387
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645389
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645391
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645393
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645395
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645397
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645399
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645401
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645403
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645405
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645407
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645409
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645411
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645413
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645415
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645417
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645419
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645421
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645423
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645425
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645427
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645429
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645431
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645433
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645435
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645437
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645439
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645441
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645443
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645445
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645447
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645449
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645451
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645453
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645455
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645457
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 06/17/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190331509
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 06/10/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190331507
Principal investigator 1 BeOne Medicines Ltd. $5,100.00 06/10/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190331511
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645227
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645229
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645231
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645233
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645235
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645237
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645239
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645241
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645243
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645245
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645247
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645249
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645251
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645253
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645255
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645257
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645259
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645261
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645263
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645265
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645267
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645269
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645271
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645273
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645275
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645277
Principal investigator 1 Boehringer Ingelheim International GmbH $262.50 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645279
Principal investigator 1 Boehringer Ingelheim International GmbH $2,704.63 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645281
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645283
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645285
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645287
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645289
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645291
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645293
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645295
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645297
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645299
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645301
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645303
Principal investigator 1 Boehringer Ingelheim International GmbH $975.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645305
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645307
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645309
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645311
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645313
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645315
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645317
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645319
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645321
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645323
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645325
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645327
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645329
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645331
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645333
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645335
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645337
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645339
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645341
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645343
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645345
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645347
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645349
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645351
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645353
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645355
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645357
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician ENCORAFENIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839003
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENCORAFENIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838363
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,507.50 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185538727
Principal investigator 1 Genentech, Inc. $91,875.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211651508
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $77,621.00 05/06/2025 Non-covered Recipient Entity
Florida Cancer Specialists - North
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235997337
Principal investigator 1 BeiGene, Ltd. $8,907.50 05/05/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323316
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,418.61 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185538723
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645171
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645173
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645175
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645177
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645179
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645181
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645183
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645185
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645187
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645189
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645191
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645193
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645195
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645197
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645199
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645201
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645203
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645205
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645207
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645209
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645211
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645213
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645215
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645217
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645219
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645221
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645223
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645225
Principal investigator 1 BeiGene, Ltd. $2,500.00 04/22/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323314
Principal investigator 1 Ipsen Bioscience Inc. $19,405.48 04/17/2025 Non-covered Recipient Entity
SARAH CANNON CANCER INSTITUTE AT HDH
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545039
Principal investigator 1 Mirati Therapeutics, Inc. $2,514.00 04/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530655
Principal investigator 1 BeiGene, Ltd. $2,500.00 04/08/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323318
Principal investigator 1 Genentech, Inc. $125.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211651222
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645105
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645107
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645109
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645111
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645113
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645115
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645117
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645119
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645121
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645123
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645125
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645127
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645129
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645131
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645133
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645135
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645137
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645139
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645141
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645143
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645145
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645147
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645149
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645151
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645153
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645155
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645157
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645159
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645161
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645163
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645165
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645167
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute North Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220645169
Principal investigator 1 Mirati Therapeutics, Inc. $13,142.25 03/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530651
Principal investigator 1 Aadi Bioscience, Inc. $10,948.75 03/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946909
Principal investigator 1 AstraZeneca UK Limited $114.29 02/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION No dispute reported 06/30/2026 1185538721
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $338.62 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists - North
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235997339
Principal investigator 1 Genentech, Inc. $4,000.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211650637
Principal investigator 1 Genentech, Inc. $140.40 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC No dispute reported 06/30/2026 1211650812
Principal investigator 1 Aadi Bioscience, Inc. $31.00 02/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946903
Principal investigator 1 Aadi Bioscience, Inc. $31.00 02/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946905
Principal investigator 1 Aadi Bioscience, Inc. $31.00 02/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946907
Principal investigator 1 Aadi Bioscience, Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946901
Principal investigator 1 BeiGene, Ltd. $2,500.00 02/11/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190324798
Principal investigator 1 ARRAY BIOPHARMA INC $650.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228853549
Principal investigator 1 Aadi Bioscience, Inc. $2,500.00 02/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946899
Recipient PFIZER INC. $330.00 01/24/2025 Covered Recipient Physician BINIMETINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839036
Principal investigator 1 BeiGene, Ltd. $2,500.00 01/21/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190324796
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,525.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185538729